Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Jul 27, 2007 by Edgar Snyder

IBS Drug Zelnorm Returns with Prescription Restrictions

Zelnorm

The dangerous drug Zelnorm has been allowed to return to market for restricted use by women less than 55 years of age suffering from irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation. The Food and Drug Administration (FDA) has permitted limited prescriptions of Zelnorm under their investigational new drug (IND) protocol, often used for serious or life threatening conditions.

Since no comparable treatment currently exists, Zelnorm will be allowed limited use under guidelines known as treatment IND. Adhering to treatment IND rules means that the age, gender, and condition requirements set forth by the FDA must be strictly followed by healthcare professionals when prescribing the medication.

Zelnorm’s marketing and sales were suspended by the FDA earlier this year when the drug was linked to heart attack, stroke, and chest pain. At that time, the FDA announced it would consider a solution similar to its IND protocol. The IBS drug will continue to remain off the market for general use.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Maryland, Ohio, and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Source: "FDA Permits Restricted Use of Zelnorm for Qualifying Patients." FDA Press Release. July 27, 2007.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet